Literature DB >> 9093354

Treatment of resistant pain in hypertrophic pulmonary osteoarthropathy with subcutaneous octreotide.

S A Johnson1, P A Spiller, C M Faull.   

Abstract

Pain in hypertrophic pulmonary osteoarthropathy (HPOA) due to periostitis and arthropathy can be a particularly disabling symptom, and resistant to a wide variety of treatments. The effectiveness of subcutaneous octreotide in relieving this pain in a patient with HPOA is reported.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9093354      PMCID： PMC1758508          DOI： 10.1136/thx.52.3.298

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  12 in total

1.  CERVICAL VAGOTOMY FOR PULMONARY OSTEOARTHROPATHY.

Authors:  M H YACOUB
Journal:  Br J Dis Chest       Date:  1965-01

2.  Osteoarthropathy in lung cancer: disappearance after section of intercostal nerves.

Authors:  C W HOLMAN
Journal:  J Thorac Cardiovasc Surg       Date:  1963-05       Impact factor: 5.209

3.  Reversal of pulmonary hypertrophic osteoarthropathy by vagotomy.

Authors:  G FLAVELL
Journal:  Lancet       Date:  1956-02-11       Impact factor: 79.321

4.  Ectopic growth-hormone production and osteoarthropathy in carcinoma of the bronchus.

Authors:  H Steiner; O Dahlbäck; J Waldenström
Journal:  Lancet       Date:  1968-04-13       Impact factor: 79.321

5.  Somatostatin, a potent analgesic.

Authors:  J Chrubasik; J Meynadier; S Blond; P Scherpereel; E Ackerman; M Weinstock; K Bonath; H Cramer; E Wünsch
Journal:  Lancet       Date:  1984-11-24       Impact factor: 79.321

6.  Plasma growth hormone and digital clubbing in carcinoma of the bronchus.

Authors:  M A Gosney; J R Gosney; M Lye
Journal:  Thorax       Date:  1990-07       Impact factor: 9.139

7.  Subcutaneous octreotide in the treatment of pain in advanced cancer patients.

Authors:  F De Conno; L Saita; C Ripamonti; V Ventafridda
Journal:  J Pain Symptom Manage       Date:  1994-01       Impact factor: 3.612

Review 8.  The aetiology of clubbing and hypertrophic osteoarthropathy.

Authors:  C J Dickinson
Journal:  Eur J Clin Invest       Date:  1993-06       Impact factor: 4.686

9.  Bone scintigraphy in growth hormone-secreting pulmonary cancer and hypertrophic osteoarthropathy.

Authors:  H Uchisako; K Suga; N Tanaka; K Nishigauchi; T Matsumoto; N Matsunaga; T Nakanishi
Journal:  J Nucl Med       Date:  1995-05       Impact factor: 10.057

10.  Lung cancer containing growth hormone-releasing hormone associated with hypertrophic osteoarthropathy. Case report.

Authors:  H Nomori; R Kobayashi; A Kubo; S Morinaga; Y Shintani; T Sano
Journal:  Scand J Thorac Cardiovasc Surg       Date:  1994
View more
  6 in total

1.  Commentary: octreotide and hypertrophic pulmonary osteoarthropathy.

Authors:  R T Penson; R M Rudd
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

Review 2.  [Hypertrophic osteoarthropathy. Bamberger-Marie disease].

Authors:  B Manger; A Lindner; K Manger; J Wacker; G Schett
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

Review 3.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

4.  Hypertrophic osteoarthropathy presenting as unilateral cellulitis with successful treatment using pamidronate disodium.

Authors:  Sebastian G Bernardo; Jason J Emer; Mark E Burnett; Marsha Gordon
Journal:  J Clin Aesthet Dermatol       Date:  2012-09

Review 5.  Paraneoplastic syndromes in rheumatology.

Authors:  Bernhard Manger; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

Review 6.  Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.

Authors:  Sheila Nguyen; Mehrnaz Hojjati
Journal:  Clin Rheumatol       Date:  2010-10-09       Impact factor: 2.980
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.